Impact of pharmacodynamics on breakpoint selection for susceptibility testing
- 1 September 2003
- journal article
- review article
- Published by Elsevier in Infectious Disease Clinics of North America
- Vol. 17 (3), 579-598
- https://doi.org/10.1016/s0891-5520(03)00062-x
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteriaJournal of Antimicrobial Chemotherapy, 2003
- Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugsInternational Journal of Antimicrobial Agents, 2002
- Pharmacodynamics of Trovafloxacin, Ofloxacin, and Ciprofloxacin against Streptococcus pneumoniae in an In Vitro Pharmacokinetic ModelAntimicrobial Agents and Chemotherapy, 1999
- Pharmacodynamic Comparisons of Levofloxacin, Ciprofloxacin, and Ampicillin against Streptococcus pneumoniae in an In Vitro Model of InfectionAntimicrobial Agents and Chemotherapy, 1999
- Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniaeJournal of Antimicrobial Chemotherapy, 1999
- State‐of‐the‐Art Clinical Article: Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and MenClinical Infectious Diseases, 1998
- Comparative Antibiotic Dose-Effect Relations at Several Dosing Intervals in Murine Pneumonitis and Thigh-Infection ModelsThe Journal of Infectious Diseases, 1989
- Correlation of Antimicrobial Pharmacokinetic Parameters with Therapeutic Efficacy in an Animal ModelThe Journal of Infectious Diseases, 1988
- Kinetics of antimicrobial activityThe Journal of Pediatrics, 1986
- Dosis-Wirkungs-Beziehung der Bakterizidie bei E. coli, K. pneumoniae und Staphylococcus aureusDeutsche Medizinische Wochenschrift (1946), 1976